1.0Cosas.iohttps://stuff.io/esStuff Adminhttps://stuff.io/es/author/nacho/rich600338<blockquote class="wp-embedded-content" data-secret="4QXPoH2EWq"><a href="https://stuff.io/es/book/fat-chance/">Fat Chance</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://stuff.io/es/book/fat-chance/embed/#?secret=4QXPoH2EWq" width="600" height="338" title="“Fat Chance” — Stuff.io" data-secret="4QXPoH2EWq" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); </script>https://stuff.io/wp-content/uploads/2026/04/fatchance512.png512512“Fat Chance” is an investigative deep dive into the GLP-1 weight loss drug boom, tracing how Ozempic and Wegovy went from diabetes meds to billion-dollar cultural forces. It alternates between real science (FDA timelines, STEP trial data, rebound weight gain studies) and patient narratives, exposing how pharma dominance, insurance discrimination, and body politics collide in